EnVVeno Medical Total Revenue Over Time
| NVNO Stock | USD 3.11 0.08 2.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out EnVVeno Medical Performance and EnVVeno Medical Correlation. EnVVeno |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EnVVeno Medical. If investors know EnVVeno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EnVVeno Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Return On Assets (0.37) | Return On Equity (0.59) |
The market value of enVVeno Medical Corp is measured differently than its book value, which is the value of EnVVeno that is recorded on the company's balance sheet. Investors also form their own opinion of EnVVeno Medical's value that differs from its market value or its book value, called intrinsic value, which is EnVVeno Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EnVVeno Medical's market value can be influenced by many factors that don't directly affect EnVVeno Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EnVVeno Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if EnVVeno Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EnVVeno Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Revenue Analysis
Compare enVVeno Medical Corp and related stocks such as Aziyo Biologics, Ainos Inc, and SurModics Total Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIMD | 1.4 M | 58.4 K | 530 | 2 K | 2 K | 2 K | 250.9 K | 250.9 K | 77.7 K | 11.7 K | 16.6 K | 594.6 K | 3.5 M | 122.1 K | 116 K |
| SRDX | 9.8 M | 51.9 M | 56.1 M | 57.4 M | 61.9 M | 71.4 M | 73.1 M | 81.3 M | 100.1 M | 94.9 M | 105.1 M | 100 M | 132.6 M | 126.1 M | 75.8 M |
| LNSR | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 26.4 M | 34.5 M | 35.4 M | 42.2 M | 37.2 M |
| IRIX | 8.8 M | 33.2 M | 33.9 M | 38.3 M | 42.8 M | 41.8 M | 46.2 M | 41.6 M | 42.6 M | 43.4 M | 36.3 M | 53.9 M | 57 M | 51.9 M | 40.7 M |
| RXST | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 14.7 M | 22.6 M | 49 M | 89.1 M | 93.5 M |
| AXGN | 4.7 M | 4.8 M | 7.7 M | 10.9 M | 16.8 M | 27.3 M | 41.1 M | 60.4 M | 83.9 M | 106.7 M | 112.3 M | 127.4 M | 138.6 M | 159 M | 167 M |
| TMCI | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 39.4 M | 57.4 M | 94.4 M | 141.8 M | 187.1 M | 114.4 M |
| LUNG | 115 K | 115 K | 115 K | 115 K | 332 K | 19.4 K | 8.8 K | 0.0 | 20 M | 32.6 M | 32.7 M | 48.4 M | 53.7 M | 68.7 M | 72.1 M |
| OFIX | 20.9 M | 579 M | 462.3 M | 400.5 M | 402.3 M | 396.5 M | 409.8 M | 433.8 M | 453 M | 460 M | 406.6 M | 464.5 M | 460.7 M | 746.6 M | 784 M |
| TNON | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 53.6 K | 43.8 K | 159.8 K | 691 K | 2.9 M | 3.1 M |
| SSKN | 210 K | 0.0 | 278.5 K | 536 K | 915 K | 18.5 M | 31.8 M | 31.4 M | 29.9 M | 29.9 M | 23.1 M | 30 M | 36.2 M | 33.4 M | 19.5 M |
| LIVN | 100 K | 218.5 M | 254.3 M | 282 M | 291.6 M | 415.7 M | 1.2 B | 1 B | 1.1 B | 1.1 B | 934.2 M | 1 B | 1 B | 1.2 B | 1.2 B |
| ELMD | 8.8 M | 19.5 M | 15.1 M | 15.5 M | 19.4 M | 23 M | 25.9 M | 28.7 M | 31.3 M | 32.5 M | 35.8 M | 41.7 M | 48.1 M | 54.7 M | 28.9 M |
| KIDS | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 31 M | 37.3 M | 45.6 M | 57.6 M | 72.6 M | 71.1 M | 98 M | 122.3 M | 148.7 M | 77.9 M |
enVVeno Medical Corp and related stocks such as Aziyo Biologics, Ainos Inc, and SurModics Total Revenue description
Total revenue comprises all receipts enVVeno Medical Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.My Equities
My Current Equities and Potential Positions
| enVVeno Medical Corp | NVNO |
| Classification | Health Management |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.11
Check out EnVVeno Medical Performance and EnVVeno Medical Correlation. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
EnVVeno Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.